Overview

* Coya Therapeutics ( COYA ) Q3 net loss narrows to $2.1 mln from $4.0 mln last year

* Company reports $3.6 mln collaboration revenue due to IND approval milestone

* Coya completes $23 mln public offering, extending cash runway into 2H 2027

Outlook

* Company expects to receive $4.2 mln milestone payment upon first patient dosing in ALS trial

* Coya plans IND submission for COYA 302 in FTD by Q4 2025

* Company anticipates extending cash runway into 2H 2027

Result Drivers

* R&D EXPENSES - Increase in R&D expenses due to clinical advancement of COYA 302 in ALS

* Research and development (R&D) expenses were $2.9 million for the three months ended September 30, 2025, compared to $2.2 million for the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$2.10

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Coya Therapeutics Inc ( COYA ) is $15.50, about 61.2% above its November 11 closing price of $6.01

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)